Europe Platelet rich Plasma Market, By Product Type (Instruments, Kits (Kit By Type (Pure Platelet-Rich Plasma (P-PRP), Leukocyte-Rich Platelet-Rich Plasma (L-PRP), Leukocyte-Platelet-Rich Fibrin (L-PRF), Pure Platelet-Rich Fibrin (P-PRF)),Kit By Origin (

Europe Platelet rich Plasma Market, By Product Type (Instruments, Kits (Kit By Type (Pure Platelet-Rich Plasma (P-PRP), Leukocyte-Rich Platelet-Rich Plasma (L-PRP), Leukocyte-Platelet-Rich Fibrin (L-PRF), Pure Platelet-Rich Fibrin (P-PRF)),Kit By Origin (Autologous Platelet-Rich Plasma, Homologus Platelet-Rich Plasma, Allogeneic Platelet-Rich Plasma))), By Application (Knee, Elbow, Foot and Ankle, Shoulder, CMF, Others) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Autologous platelet-rich plasma (PRP) is a blood plasma concentrate enriched with platelet count above the baseline of whole blood prepared from patient’s own blood. PRP is injected directly at the site of inflamed tissue releasing growth factor which stimulates and increases number of reparative cell in patient body. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. PRP is used for treatment of injured tendons, ligaments, muscles and joints Increasing prevalence of musculoskeletal injuries along with increasing prevalence of knee osteoarthritis is expected to boost growth of Europe platelet-rich plasma market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global Platelet-rich Plasma and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global Platelet-rich Plasma based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., and Estar Technologies Ltd.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global Platelet-rich Plasma report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Europe Platelet-rich Plasma Market, By Product Type:
Instruments
Kits
Kit By Type
Pure Platelet-Rich Plasma (P-PRP)
Leukocyte-Rich Platelet-Rich Plasma (L-PRP)
Leukocyte-Platelet-Rich Fibrin (L-PRF)
Pure Platelet-Rich Fibrin (P-PRF)
Kit By Origin
Autologous Platelet-Rich Plasma
Homologus Platelet-Rich Plasma
Allogeneic Platelet-Rich Plasma
Europe Platelet-rich Plasma Market, By Application:
Knee
Elbow
Foot and Ankle
Shoulder
CMF
Others
Europe Platelet-rich Plasma Market, By Country/Region:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Company Profiles
Arthrex, Inc.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Stryker Corporation
Johnson and Johnsons Ltd.
Zimmer Biomet Holdings Inc.
Terumo Corporation
Glofinn Oy
Medira Ltd.
Regen Lab S.A.
Estar Technologies Ltd.
“*” marked represents similar segmentation in other categories in the respective section.